temporal

The HEMOSTASIS CONNECT European Collaborative Haemophilia Network (ECHN) Group is proud to announce the publication of the paper: Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?


The development of inhibitors to factor VIII (FVIII) is a serious complication of clotting factor replacement therapy associated with increased morbidity and mortality. According to guidelines patients with inhibitors should have access to immune tolerance induction (ITI) for eradication of inhibitors and to suitable haemostatic agents at specialized centres. 

The European Collaborative Haemophilia Network (ECHN) conducted a survey on the use of ITI in Europe.  Results have recently been published in the journal Haemophilia.

Access the publication and download the summary slide kit.

 

Dr. Holstein will be hosting a webinar on ITI on Wednesday June 1st as part of the National Hemophilia Foundation Wednesday Webinar series.

Katharina Holstein is currently working at the Haemophilia and Thrombosis Centre at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, since 2004. After receiving her medical degree at the University of Hamburg in 1992, she worked in the department of Internal Medicine at the General Hospital Eilbek Hamburg, Germany, and in the department of Haematology and Oncology at the University Hospital Hamburg-Eppendorf from 1995. Her specialties include internal medicine, haematology, oncology and haemostaseology with a special focus on haemophilia. Dr Holstein’s field of interest is improvement of care for people with haemophilia. She has taken part in several clinical trials and studies and has focused mainly on haemophilia treatment since 2004. She is a reviewer for several haematology journals and has published several articles in the field of haemophilia. Her special research interests are joint and bone health, pain management, bleeding phenotype and treatment of inhibitors in patients with haemophilia.

Dr Katharina Holstein has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Biotest, CSL Boehringer, NovoNordisk, Pfizer, Roche/Chugai, Sobi and Takeda. 

Lund University and Skåne University Hospital in Malmö, Sweden. Jan Astermark is Professor in Clinical Coagulation Medicine at Lund University, Senior Consultant and Director of the Center for Thrombosis and Hemostasis in Malmö and Assistant Head of the Department of Translational Medicine in Malmö/Lund, Sweden. He is a specialist in haematology, coagulation disorders and internal medicine. He is a reviewer for haematology journals, and has published a number of original articles, review articles and book chapters in the field of haemophilia and coagulation disorders.

Prof. Jan Astermark has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, CSL Behring, Novo Nordisk, Octopharma, Roche, Sobi and Takeda/Shire. 

Víctor Jiménez-Yuste is Associate Professor of Medicine at the Universidad Autónoma de Madrid and Head of the Haematology Department at the Hospital Universitario La Paz (Madrid, Spain). After his degree in Medicine at the University of Valladolid, he specialised in haematology at the Hospital Universitario La Paz. He was awarded his PhD by the Autónoma University of Madrid where he completed his thesis studying haemophilia and HIV infection. Professor Jiménez-Yuste is a member of the executive committee of the Spanish Society of Haematology and Haemotherapy. His lines of research include the treatment of hereditary coagulation disorders, ITP, and acquired haemophilia. He has published more than 200 articles in different journals on these topics.

Prof. Victor Jiménez-Yuste has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BioMarin, CSL Behring, Grifols, Novo Nordisk, Octopharma, Pfizer, Roche, Sobi and Takeda. 

Pål Andrè Holme is Professor of Haematology and Senior Haematologist at the Department of Haematology and Institute of Clinical Medicine, Oslo University and Oslo University Hospital, Rikshospitalet, Norway. He graduated from the Medical School at the University of Oslo in 1993 and was a research fellow at the Institute for Internal Medicine, University of Oslo, where he earned a PhD in 1996 after studies on platelet activation and platelet-derived-microparticle formation. He is a specialist in internal medicine and haematology. Prof. Holme has been responsible for the treatment of adult patients with haemophilia and bleeding related disorders in Norway since 2006. He leads a research group at Institute of Clinical Medicine and participates in several clinical research groups and has for a long time been an active investigator in studies on bleeding related disorders and platelets, and has authored many papers published in peer-reviewed journals and textbook chapters on these subjects.

Prof. Pål Andrè Holme has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Octopharma, Pfizer, Sobi and Takeda. 

Angelika Batorova is a Medical Director of the National Hemophilia Centre and Hemostasis and Thrombosis Unit of the Department of Hematology and Transfusion Medicine, University Hospital, Bratislava. Dr Batorova received her medication education from Comenius University, Bratislava, where she specialised in Internal Medicine, Hematology and Transfusion Medicine. In 1992 she obtained the PhD and in 2004 the position of Associate Professor at the Medical School of Comenius University and at the Postgraduate Medical School, both in Bratislava. The fellowship and visiting appointments included the National Hemophilia Centre in Tel Aviv, the New York Blood Centre, and the Hemophilia Comprehensive Care Centers in New York. Dr Batorova’s fields of interests is the optimisation of hemophilia treatment, including the treatment of inhibitors, management of surgery, continuous infusion of coagulation factors as well as the comprehensive care for congenital factor VII deficiency. Dr Batorova has worked as a member of the Executive Committee and the Medical Advisory Board of the World Federation of Hemophilia 2006 – 2010 and currently she is a member of the Data and Demographic Committee of the WFH and the Medical Advisory Group of the European Haemophilia Consortium.

Prof. Angelika Batorova has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

CSL Behring, Novo Nordisk, Octopharma, Roche, Sobi and Takeda. 

Dr Sandra Le Quellec, MD PhD, is a dedicated haematologist and Associate Professor of Medicine at the University of Claude Bernard Lyon I, Lyon, France. She earned her medical degree and completed a 4-year haemostasis fellowship at both the Haemophilia Comprehensive Care Centre of Lyon, and the Laboratory of Haematology, Lyon, France. Meanwhile, she earned her PhD degree on gene therapy for haemophilia, for which she had worked in collaboration with two research laboratories: EA4609 – Haemostasis and Cancer (Prof. Claude Négrier) at the University Claude Bernard Lyon I, Lyon, France and the Research Laboratory of Haematology (Prof Amit Nathwani) at the University College of London, United Kingdom. Currently, she participates in the clinical care of patients with either bleeding or thrombotic disorders, she is responsible for the department of platelet function analyses in the laboratory of haematology. Her main research interest relies in the development of therapeutic options for haemophilia.

Assoc. Prof. Sandra Le Quellec has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, CSL Behring, LFB, Octopharma, Roche/Chugai, Sobi and Takeda. 

Dr Robert Klamroth received his medical degree in 1994, and went on to gain his PhD in 1996 at Free University, Berlin, Germany. Here he took the position of Academic Assistant of the Clinic for Internal Medicine and Complementary Medicine, University Medical Centre, and then became Assisting Consultant / Senior Consultant of the Department for Coagulation Disorders / Haemophilia Treatment Centre of the Hospital in Friedrichshain, Berlin, a position which he held until 2001 when he received his specialisation in internal medicine. Since 2001, Dr Klamroth has been Assistant Medical Director at the Clinic for Internal Medicine, Angiology and Coagulation Disorders, and Director of the Haemophilia Treatment Centre and the Department of Coagulation Disorders at the Vivantes Hospital in Friedrichshain, Berlin. Since 2014 he has been head of the Department for Internal Medicine and Vascular medicine at this hospital. Since 2017 he has been Associate Professor of Coagulation Disorders at the University of Bonn. Since 1997, Dr Klamroth has published more than 100 manuscripts in the field of haemophilia and coagulation disorders, and made many academic contributions on coagulation disorders, as well as participating in clinical studies in this field. His major research interest is haemophilia in adults. Dr Klamroth is the vice president of for the European Association of Haemophilia and Allied Disorders (EAHAD) and holds membership of various national and international societies in the field of angiology, thrombosis and haemostasis. He also serves as Vice President at the German Society of Thrombosis and Haemostasis (GTH).

Assoc. Prof. Robert Klamroth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Biotest, Biomarin, CSL Behring, LEO, Novo Nordisk, Octopharma, Pfizer, Roche/Chugai, Sanofi, Sobi and Takeda. 

Podcast on immune tolerance induction

Prof. Jan Astermark and Dr. Katharina Holstein discuss their views on the use of ITI in haemophilia

Experts
Prof. Jan Astermark, Dr Katharina Holstein
  • download Downloadable
    Resouces
  • clock 25 MIN
  • calendar Apr 2022
This educational programme is supported by an Independent Medical Education Grant from Takeda
Programme summary
Read the publication now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Takeda
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts

Other programmes of interest

podcast Podcast
Hemostasis and bleeding disorders 
Thrombophilia: Clinical overview and impact on patients

Part 1 of a thrombophilia podcast series

Experts
Prof. Cedric Hermans, Prof. Sabine Eichinger
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2024

Educational programme supported by an Independent Medical Education grant from Pentapharm.
video Video
Hemostasis and bleeding disorders 
MOVE Haemophilia 2023

Implementing international guidelines and best practices for hemophilia in clinical practice

Experts
Prof. Ana Boban, Dr Christoph Königs, Prof. Jan Astermark, Prof. Pratima Chowdary, Dr Steven Kitchen, Dr Sebastien Lobet
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Medical Education grant from Sobi.
podcast Podcast
Rare diseases Hemostasis and bleeding disorders 
Rare diseases: gene therapy and gene-modified cell therapies

Current role, potential and the example of hemophilia

Experts
Prof. Cedric Hermans, Prof. Miguel Escobar
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Medical Education grant from American Society of Gene + Cell Therapy and Pfizer.
podcast Podcast

Episode

4

of 4

episode
Hemostasis and bleeding disorders 
Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Experts
Prof. Dimitrios Tsakiris, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 19 MIN
  • calendar Nov 2023

Educational programme supported by an Independent Medical Education grant from Viatris.
podcast Podcast

Episode

3

of 4

episode
Hemostasis and bleeding disorders 
VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Experts
Prof. Dimitrios Tsakiris, Prof. Jerzy Windyga
Endorsed by
Fundacja Trombofilia i Zakrzepica
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Oct 2023

Educational programme supported by an Independent Medical Education grant from Viatris.
podcast Podcast

Episode

2

of 4

episode
Hemostasis and bleeding disorders Oncology 
Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Medical Education grant from Viatris.